Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation

Award Number: R43CA193101
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/13/2016
PERIOD OF PERFORMANCE END DATE: 11/30/2016

Group Awards By:

View Award Description

Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation - ¿ DESCRIPTION (provided by applicant): Thanks to their exquisite specificity and sensitivity, monoclonal antibodies (Mab) are the most important research tool for detection, localization and quantification of cellular proteins and widely used for diagnosis and treatment of various human diseases. Conventional hybridoma approach for generating monoclonal antibodies is time-consuming, labor intensive and multistep process that requires immortalization of splenocytes by fusion to a myeloma cell line partner. To simplify the generation of antibodies and to increase the productivity, a novel hybridoma-free multiplex approach for accelerating antibody discovery is proposed. The objective will be achieved by multiple antigen immunization into transgenic H-2Kb-tsA58 mice harboring a mutant temperature-sensitive simian virus 40 large tumor antigen. Antibody-producing B cells stained with fluorescence-labeled antigens will be isolated by fluorescence activation cell sorting (FACS). Sorted antigen-specific splenocytes will be conditionally immortalized by culturing at permissive temperatures. In Phase I, the proposed approach will be validated by developing highly specific monoclonal antibodies to 10 cancer-related targets. In Phase II, the platform will be used to develop mouse monoclonal antibodies to at least 100 protein targets that are involved in cancer. Compared with traditional approach, the time required for Mab generation using this approach is expected to reduce at least in half, while ten-fold or more increasing antibody generation productivity with significant improvement of target-specificity due the selection criteria used during FACS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2016	ABZYME THERAPEUTICS, LLC	321 JONES BLVD, STE 300	POTTSTOWN	PA	19464	MONTGOMERY	USA	Cancer Biology Research	000	1	3/1/2017	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $39,966 )
2016	2016	ABZYME THERAPEUTICS LLC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Cancer Biology Research	000	1	3/9/2016	SUPPLEMENT FOR EXPANSION	$39,966
														Subtotal = $39,966

Issue Date FY: 2015 ( Subtotal = $224,781 )
2015	2015	ABZYME THERAPEUTICS LLC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Cancer Biology Research	000	1	4/30/2015	NEW	$224,781
														Subtotal = $224,781

Grand Total All Awards = $264,747

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation

Award Number: R43CA193101

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/13/2016

PERIOD OF PERFORMANCE END DATE: 11/30/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer